Who are Continuous Docetaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paclitaxel (Pac), Nab-paclitaxel/Paclitaxel, Paclitaxel (X), Docetaxel injection, Paclitaxel (Taxane), Nab-paclitaxel （neoadjuvant）.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/continuous-docetaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Continuous Docetaxel — Competitive Intelligence Brief

Continuous Docetaxel (Continuous Docetaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane (microtubule stabilizer). Area: Oncology.

phase 3 Taxane (microtubule stabilizer) β-tubulin / microtubules Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Continuous Docetaxel (Continuous Docetaxel) — University of Turin, Italy. Continuous docetaxel is a taxane chemotherapy agent that stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and disrupting cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Continuous Docetaxel TARGET	Continuous Docetaxel	University of Turin, Italy	phase 3	Taxane (microtubule stabilizer)	β-tubulin / microtubules
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules
Nab-paclitaxel/Paclitaxel	Nab-paclitaxel/Paclitaxel	BioNTech SE	phase 3	Microtubule stabilizer / Taxane	β-tubulin / Microtubules
Paclitaxel (X)	Paclitaxel (X)	Merck Sharp & Dohme LLC	phase 3	Taxane; microtubule stabilizer	β-tubulin / microtubules
Docetaxel injection	Docetaxel injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Taxane (microtubule stabilizer)	β-tubulin / microtubules
Paclitaxel (Taxane)	Paclitaxel (Taxane)	Eli Lilly and Company	phase 3	Taxane (microtubule-stabilizing agent)	β-tubulin / microtubules
Nab-paclitaxel （neoadjuvant）	Nab-paclitaxel （neoadjuvant）	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	phase 3	Microtubule stabilizer / Taxane	β-tubulin / Microtubules

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane (microtubule stabilizer) class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Infinity Pharmaceuticals, Inc. · 1 drug in this class
Sanofi · 1 drug in this class
University of Turin, Italy · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Continuous Docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/continuous-docetaxel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab